Meeting
2021 Genitourinary Cancers Symposium
Safety and efficacy outcomes in immune checkpoint inhibitor (ICI)-treated metastatic urothelial carcinoma (mUC) patients (pts) requiring treatment interruption (TI) due to immune-related adverse events (irAEs).
Authors
Amanda Nizam
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Amanda Nizam , Iris Yeong- Fung Sheng , Kimberly D. Allman , Allison Martin , Timothy D. Gilligan , Shilpa Gupta , Moshe Chaim Ornstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 411)
DOI
10.1200/JCO.2021.39.6_suppl.411
Abstract #
411
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of body mass index (BMI) on efficacy of immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: David Lynn
Poster
2023 ASCO Annual Meeting
Safety of checkpoint inhibitors in older patients with genitourinary cancers.
First Author: Brian Hemendra Ramnaraign
Poster
2022 ASCO Annual Meeting
Extended interval dosing in patients with cancer receiving immune checkpoint inhibitors: Safety analysis from the EDICI study.
First Author: Luca Cantini
Poster
2024 ASCO Genitourinary Cancers Symposium
Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: Nikhil Pramod